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Background/aim: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease
symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinibinduced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas.
However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics
study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders.
Materials and methods: The gene expression data were retrieved from the E-MTAB-783 Cancer Genome Project database. Gene
expression data for all available genes in 26 cell lines belonging to various types of lymphomas were chosen for use in this in silico
analysis.
Results: We identified genes that were significant in developing resistance to ruxolitinib in lymphoma cell lines.
Conclusion: Based on the results of our present study, ruxolitinib may potentially lead to the pathological expression of the transcription
factors important in lymphoma genesis, neoplastic commitment on the progenitor lymphoid cells, inhibition of repressor transcriptions
protective for lymphoma development, inhibition of apoptosis, promotion of neoplastic proliferation, transcriptional activation, and
proliferation of malignant neoplastic B cells.
Key words: Lymphoma, ruxolitinib, JAK/STAT signaling pathway

1. Introduction
Ruxolitinib, a novel oral JAK 1 and 2 inhibitor, was
newly certified as a revolutionary treatment for patients
suffering from intermediate/high risk myelofibrosis (1). It
was demonstrated that the exposure of cutaneous T-cell
lymphoma cell lines triggered a dose-dependent inhibition
of cell proliferation by a mechanism that impacted the
control of DNA synthesis, with a significant decline in the
basal levels of phospho-STAT3 (2).
Furthermore, the ruxolitinib-mediated decrease in
circulating proinflammatory cytokine levels is connected
to its inhibitory effects on JAK1-mediated signaling; this
may make ruxolitinib a tempting therapeutic agent for
MYD88 mutation-positive lymphoma patients, as this
mutation leads to cell-autonomous activation of JAK 1
and JAK 2 (3). JAK/STAT signaling has been detected to
be vital in the mammary gland, lymphocytes, adipocytes,
neuronal cells, cardiomyocytes, hepatocytes, eye cells,

and stem cells. Deregulation in the JAK/STAT pathway is
suggested as a cause of numerous diseases including the
emergence and the advancement of cancer cells (4).
The JAK/STAT pathway controls embryonic
development and is also a part of the regulation of many
processes such as stem cell maintenance, hematopoiesis,
and the inflammatory response (5). STATs have critical
as well as nonredundant functions in lymphocyte
development. They impact cell fate decisions like
differentiating naive T cells, regulate the intensity and
period of inflammatory responses, and contributes to
pathogenic mechanisms in chronic inflammatory diseases.
STAT3 governs the differentiation of naive T cells into
the regulatory and inflammatory T-cell lineages. It also
controls cell growth, apoptosis, and the transcription of
inflammatory genes, and it contributes to the development
of chronic inflammatory diseases, as well as malignant and
neurodegenerative diseases (5). STATs are also known to
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control counteracting cellular events by contributing to the
induction of apoptosis, as well as in differentiation and stem
cell maintenance. STAT3 signaling throughout mammary
gland involution induces epithelial cell death. In opposition
to this, persistent and enhanced STAT3 activation is
an initiator of tumorigenesis (5). Moreover, JAK/STAT
signaling leads to immunosuppression and controls
inflammatory responses, obesity, stem cell maintenance,
and the premetastatic niche development. These effectors
and the direct and mediated mechanisms of JAK/STAT
signaling in and on tumors cells improved our outlooks for
JAK/STAT-based cancer therapeutics (5).
The aim of this bioinformatics study is to detect any
possible confounding effects of ruxolitinib on the genesis
of lymphoproliferative disorders. Recently, it has been
proposed that ruxolitinib-induced JAK/STAT pathway
inhibition in myelofibrosis is associated with an elevated
frequency of aggressive B-cell lymphomas (6). Elucidation of
this unique drug acting on multiple biological downstream
paths is important since it is already accepted as a standard
medication for the real-life management of patients with
chronic myeloproliferative disorders, namely myelofibrosis
and polycythemia vera (PV) (7,8). The management of
such patients is based on randomized clinical trials such
as the COMFORT-I, COMFORT-II, and RESPONSE trials
and real-life administration data (9–11). However, chronic
myeloproliferative disorders are relatively benign diseases in
comparison to the acute myeloproliferation. Therefore, there
is a general safety concern for the long-term administration
of ruxolitinib, particularly for the emergence of secondary
malignancies such as lymphomas (9,10). Hence, the findings
of this study can underline the complication of lymphoma
development with the probable relative long-term usage of
ruxolitinib as a JAK/STAT signal transduction inhibitor (6).
2. Materials and methods
2.1. Microarray gene expression and drug cytotoxicity data
The gene expression data used in this study were retrieved
from the E-MTAB-783 Cancer Genome Project (CGP)
database and RMA-normalized (12). The database contained
data for 13,513 genes, amounting to 22,279 probe sets.
The expression of these genes in 773 cell lines, belonging
to a variety of cancer types, was available. Out of these,
gene expression data for all available genes in 26 cell lines
belonging to various types of lymphomas (B-cell lymphoma,
Burkitt lymphoma, and Hodgkin lymphoma) were chosen
for use in in silico analysis. The drug cytotoxicity data for
ruxolitinib were obtained from the E-MTAB-783 CGP
database for drug sensitivity (12).
2.2. Identification of the genes whose expressions correlated with ruxolitinib sensitivity
The previously retrieved and RMA-normalized gene
expression data for 13,513 genes in 26 lymphoma cell
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lines (B-cell lymphoma, Burkitt lymphoma, and Hodgkin
lymphoma) were correlated with drug cytotoxicity data
for ruxolitinib. Using Pearson correlation analysis, genes
that could be associated with ruxolitinib sensitivity were
identified.
From this analysis, genes with the highest correlation
were then used for further analysis. A list of genes
containing all the genes that we were especially interested
in investigating was compiled. The selection criteria
of genes included clinicopathological correlation of
lymphoma genesis and ruxolitinib administration. During
the selection of genes, a clinician and molecular biologist
worked together in order to determine clinically relevant
and biologically important genes to underline the research
endpoints. These genes are henceforth referred to as genes
of interest in this study and are compiled in Table 1. This
list had 200 genes; 155 belonged to the JAK/STAT pathway,
31 were cancer stem cell (CSC) markers, and 14 were
immune response markers.
The highly correlated genes from the Pearson
correlation analysis were then searched to see if any of them
were genes of interest. Following this, the top 10 directly
correlated genes and top 10 inversely correlated genes that
were highly correlated were selected. Lymphoma cell lines
were hierarchically clustered based on these genes, using
Gene Cluster 3.0 with Euclidean distance as a similarity
metric parameter for genes and arrays, and complete
linkage.
2.3. Determination of differentially expressed genes
within resistant and sensitive groups
We had gene expression data for 26 lymphoma cell lines.
We decided to divide these cell lines into two groups based
on IC50 values for ruxolitinib to see if we could distinguish
between cell lines that were sensitive to ruxolitinib and cell
lines that were resistant to ruxolitinib.
A bar chart and a heat-map were generated in Excel
from the IC50 values to visualize the increase in IC50 values
across the 26 cell lines. A two-tailed, unpaired t-test was
performed between cell lines with the lowest IC50 values,
the sensitive group (HDLM2, TUR, BC3), and cell lines
with the highest IC50 values, the resistant group (RAJI,
DG75, RPMI6666, DB). P < 0.05 was determined to be an
appropriate standard for selection of the two groups.
The 200 genes of interest, containing 155 JAK/STAT
pathway genes, 31 CSC markers, and 14 immune response
markers, were now analyzed within the sensitive group
(HDLM2, TUR, BC3) and resistant group (RAJI, DG75,
RPMI6666, DB). A two-tailed, unpaired t-test was used to
verify which genes were differentially expressed in the two
groups. A cut-off of 0.05 was used for the P-values.
Separate hierarchical clusters were first created for all
26 lymphoma cell lines and then for only the 7 cell lines
in the two groups, based on the significant differentially
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Table 1. List of genes of interest used as the basis of this study.
Genes of interest
Total = 200
JAK/STAT Genes*

Cancer stem cell (CSC)
markers**

Immune response
markers***

Total = 155

Total = 31

Total = 14

GH1, TIMP-1, CSH1, PIK3CB, PIAS3, MPL, APP, IFNAR1, IL6R, AKT1, AKT2,
AKT3, AP1, BCL2L1, CBL, CBLB, CBLC, CCND1, CCND2, CEBPB, CISH,
CLCF1, CNTF, CNTFR, CREBBP, CRLF2, CSF2, CSF2RA, CSF2RB, CSF3, CSF3R,
CTF1, EGF, EGFR, EP300, EPO, EPOR, ERK, GH2, GHR, GRB2, IFNA1, IFNA14,
IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA8, IFNAR2, IFNB1,
IFNG, IFNGR1, IFNGR2, IFNW1, IL10, IL10RA, IL10RB, IL11RA, IL12A, IL12B,
IL12RB1, IL12RB2, IL13,

CD22, CD27, CD19,
CD20, CD40, CD45,
ALDH1A1, CCND1,
CD10, CD133, CD138,
CD15, CD23, CD25,
CD30, CD34, CD4, CD43,
CD44, CD5, CD7, CD71,
CD77, CD80,

CD278, CD279,
CD3D, CD3E,
CD3G, CD4, CD47,
CD68, CD8, CTLA4,
FoxP3, IDO-1,
LAG3, MUM1

IL13RA1, IL13RA2, IL15, IL15RA, IL19, IL2, IL20RA, IL21, IL21R, IL22, IL22RA1,
IL23A, IL24, IL26, IL2RA, IL2RB, IL2RG, IL3, IL3RA, IL4, IL4R, IL5, IL5RA,
IL6, IL6ST, IL7, IL7R, IL9, IL9R, IRF9, JAK1, JAK2, JAK3, LEP, LEPR, LIF, LIFR,
Mcl-1, MEK2, MTOR, MYC, NFKB1, NFKB2, OSMR, P120, PIAS1, PIAS2, PIAS4, CD8A, LMP1, MMP2,
PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PIM1, PRL, PRLR, MMP7, MMP9, TGFB1
PTPN1, PTPN11, PTPN2, PTPN6, RAF1, SHC1, SOCS1, SOCS2, SOCS3, SOCS5,
SOCS7, SOS1, SOS2, SPRED2, SPRY1, SPRY2, SPRY4, SRC, STAM, STAM2,
STAT1, STAT2, STAT3, STAT5A, STAT5B, STAT6, SUMO1, TF, TPO, TYK2

*Genes that are a part of the JAK/STAT mediated signaling pathway. **Genes that are known to be cancer stem cell markers within
lymphoma. ***Genes belonging to the immune response pathway that are identified as markers for lymphoma.

expressed genes. The clustering was done using Gene
Cluster 3.0 with Euclidean distance as a similarity metric
parameter for genes and arrays, and complete linkage.
2.4. Gene-set enrichment analysis
The gene expression data for all 13,513 genes found in the
E-MTAB-783 CGP database, and for the 7 cell lines in the
sensitive group (HDLM2, TUR, BC3) and resistant group
(RAJI, DG75, RPMI6666, DB), were put into GSEA 3.0 to
determine which genes were significantly different within
the two groups. Furthermore, we wanted to highlight the
pathways that these genes were a part of in both these
groups (12).
2.5. Network analysis
Out of the 200 genes of interest, the 25 genes that were
differentially expressed were used as input for the
GeneMANIA app (13) in Cytoscape (14) to generate a
network based on coexpression and genetic interactions.
That was done in order to find if the two sets have
functionally similar genes related to each other and to
determine the associated functions for different groups
of genes in the network. The network served as a starting
point for the pathway analysis approach in Reactome (15)
to filter out regulatory pathways that are relevant for both
these gene sets.

3. Results
We identified genes that were significant in developing
resistance to ruxolitinib in lymphoma cell lines. We used
a statistical approach that allowed us to correlate the IC50
data for ruxolitinib and gene expression for desired genes
and create a linear relationship between the two.
3.1. Genes correlated with ruxolitinib sensitivity
The gene expression data for all 13,513 genes in the
E-MTAB-783 CGP database for lymphoma cell lines were
analyzed (12). By doing Pearson correlation analysis with
these genes, we were able to find the most highly correlated
genes with ruxolitinib sensitivity. A cut-off of 0.4 was used
for the R-values so that a large number of genes could
be considered. With this cut-off, 800 genes were shown
to be highly correlated with a direct relationship while
584 were shown to be highly correlated with an inverse
relationship. Further analyses were done using these
highly correlated genes. Of these highly correlated genes,
we found a number of genes that were of interest to us.
We had compiled a list of 200 genes for this study that we
wanted to investigate. The list contained 155 JAK/STAT
pathway genes, 31 CSC markers, and 14 immune response
markers. Our analysis showed that 4 JAK/STAT pathway
genes had a direct relationship with ruxolitinib resistance,
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while 8 JAK/STAT pathway genes showed an inverse
relationship. Figure 1A shows one of the genes, CSF2RA,
which has an inverse relationship with the development of
ruxolitinib resistance. On the other hand, we also found a
direct linear relationship between the expressions of 5 CSC
markers and resistance to the drug. Figure 1B shows the
correlation of one of these genes, CD45. Unfortunately, no
immune response markers were found among the highly
correlated genes. Following this, the ten highest directly
correlated genes and the ten highest inversely correlated
genes were hierarchically clustered. The results shown in
Figure 2 show the presence of two distinct clusters within
lymphoma cell lines.
3.2. Determination of sensitive and resistant groups
within lymphoma cell lines
The 26 available lymphoma cell lines were divided into two
groups, where one group was significantly more resistant
to ruxolitinib than the other. Significance was determined
by performing a two-tailed, unpaired t-test between the
groups and accepting P-values of less than 0.05.
IC50 data for ruxolitinib were plotted for each cell
line available. As a result, a comparative bar chart was
created, as shown in Figure 3. This allowed for the clear
determination of the level of sensitivity of each cell line to
ruxolitinib. A heat-map was created to further highlight
the range of sensitivity to ruxolitinib in lymphoma cell
lines, also seen in Figure 3. Based on the bar chart and
the heat-map, the cell lines were divided into two groups.
The sensitive group (HDLM2, TUR, BC3) included the
cell lines that corresponded to the lowest ruxolitinib IC50
values, hence being the most sensitive to this drug. The
resistant group (RAJI, DG75, RPMI6666, DB) included
the cell lines that corresponded to the highest ruxolitinib

IC50 values, being the least sensitive and most resistant
to action of this drug. The resistant group, compared to
the sensitive group, was significantly more resistant to
ruxolitinib, with a P-value of 0.001.
3.3. Differentially expressed genes within resistant and
sensitive groups
The E-MTAB-783 CGP database for gene expression in
cancer cell lines was used with a focus on the lymphoma
cell lines that were part of the resistant and sensitive
groups (12). Analysis of the comparative gene expression
between these two groups revealed that 904 genes were
differentially expressed, with P-values of less than 0.05.
The results further showed that out of these 904 genes, 15
belonged to the list of 200 genes of interest that we had
compiled for this study. These 15 genes are displayed in
Table 2 along with their classifications; 9 of these genes
are involved in the JAK/STAT pathway while 6 are CSC
markers. These genes and their clinical significance are
shown in Table 3. This allowed us to form a relationship
between the expression of genes of interest and ruxolitinib
sensitivity. To further demonstrate this relationship,
differentially expressed genes for the JAK/STAT pathway
and CSC markers were hierarchically clustered, as shown
in Figure 4 and Figure 5, respectively. These figures can be
seen having two distinct clusters.
3.4. Gene-set enrichment analysis
Gene-set enrichment analysis was then performed between
the sensitive and resistant groups of the lymphoma cell lines.
The analysis was performed with all the genes available
in the E-MTAB-783 CGP database (12). The results
highlighted the genes that showed significant differences
between the two groups and provided us with insight about
which pathways these significant genes were involved in.

Figure 1. Identification of highly correlated genes. Among the genes that were analyzed with ruxolitinib drug cytotoxicity data, CSC
biomarkers and JAK/STAT pathway genes were among the highly correlated. CD45, A, shows the highest direct correlation among the
CSC biomarkers with an r value of 0.54. CSF2RA, B, shows the highest inverse correlation amongst the JAK/STAT pathway genes with
an r value of –0.58.
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Figure 2. Highly correlated genes show the presence of distinct groups within lymphoma. The top ten directly
correlated genes along with the top ten inversely correlated genes were hierarchically clustered with all available
lymphoma cell lines. All gene expressions used were standardized.

Figure 3. The sensitive and resistant groups show significant changes in ruxolitinib IC50.
The cell cytotoxicity data for ruxolitinib available in the E-MTAB-783 CGP database
were compared for each lymphoma cell line. The bar chart above shows the vast range
of IC50 for lymphoma cell lines, which allowed us to create two distinct groups. The
selected groups were significant with a P-value of 0.001 (20).
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Table 2. List of genes of interest that are differentially expressed
within resistant and sensitive groups.
Significant genes
JAK/STAT pathway

CSC markers

GH1 (P = 0.0066)

CD22 (P = 0.0170)

TIMP-1 (P = 0.0181)

CD27 (P = 0.0013)

CSH1 (P = 0.0342)

CD19 (P = 0.0035)

PIK3CB (P = 0.0224)

CD20 (P = 0.0145)

PIAS3 (P = 0.0312)

CD40 (P = 0.0228)

MPL (P = 0.0316)

CD45 (P = 0.0275)

APP (P = 0.0339)
IFNAR1 (P = 0.0339)
IL6R (P = 0.0376)

Table 4 and Table 5 respectively show the pathways that
were found to be statistically noteworthy, with P-values of
less than 0.05, within the sensitive and the resistant groups.
3.5. Network analysis
Our previous analysis had revealed that 15 of 200 genes
of interest were differentially expressed in the sensitive
and resistant groups. Nine of these belonged to the JAK/
STAT pathway while the other 6 were CSC markers.
These 15 genes were input into the GeneMANIA app in
Cytoscape to generate a network based on coexpression
and genetic interactions. Cytoscape tools were used to
differentiate the input genes from both sets from the ones
that GeneMANIA predicts as likely to share the same
function based on their interactions, as seen in Figure 6.
From the network, it is distinctly clear that the two sets
of genes are connected with one another. Furthermore,
the results of GeneMANIA analysis provided a list of
associated functions for different groups of genes in the
network, as shown in Table 6. The integration of different

Table 3. List of lymphoid cancer stem cell genes that are affected via ruxolitinib usage and their clinical correlations.
Gene*

Physiological function**

Pathobiological
alteration**

Possible disordered
mechanism**

Related lymphoid
neoplasms**

B-Cell related genes*
CD19
CD20
CD23
CD25
CD22

B-lymphocyte
development, growth,
differentiation,
determination of B-cell
functions

Neoplastic aberrations
resulting in numerous
lymphoid malignant
disorders

Pathological expression of
the transcription factors,
proliferation of malignant
neoplastic B cells

T-cell lymphoma (21)
B-cell lymphoma (22,23)
Hodgkin lymphoma (24,25)
Follicular lymphoma (26,27)

T-Cell related genes*
CD5
CD10
LMP-1

T-cell proliferation,
inactivation of critical
peptide hormones
important for lymphoid
functions

Pathological
alterations of
transmembrane
Inhibition of cellular
glycoproteins and
apoptosis
lymphoid cell surface
markers

Lymphoid / lineagerelated genes*
CD45
CD30
CD15
CD79
CD138
CD38
CD43
CD71

Regulation of signaling,
lymphoid cellular
processes including cell
growth, differentiation,
mitosis, oncogenic
transformation, and
immune activation

Pathological
alterations of cellular
proliferation,
migration, and cell–
matrix interactions

Neoplastic proliferation of
B-lymphoid cells and
plasma cells

CLL
SLL
MCL (29)
Nasal NK/T-cell lymphoma
(30)
DLBCL (31), NK/T-cell
lymphoma (32), AITL (33),
PTCL (NOS) (34),
Hodgkin lymphoma (34),
PTCL (35),
extranodal NK/T-cell
lymphoma (36),
DLBCL (37),
DLBCL (37), ATLL (20)

*Genes affected by ruxolitinib treatment. **Selected physiological actions, pathobiological alterations, possible mechanisms for the
genesis of lymphoid neoplasms. CLL: Chronic lymphocytic leukemia, SLL: small lymphocytic lymphoma, MCL: mantle cell lymphoma,
DLBCL: diffuse large B cell lymphoma, AITL: adult T-cell leukemia/lymphoma, PTCL: Peripheral T-cell lymphoma, ATLL: adult T-cell
leukemia/lymphoma.
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Figure 4. Clustering of lymphoma cell lines with differentially expressed CSC markers. The CSC markers that were differentially
expressed were first hierarchically clustered with all available lymphoma cell lines as shown in A. These same genes were then clustered
with only the sensitive and resistant group cell lines, as shown in B. In both cases two major clusters can be seen, one with sensitive cells
and the other with resistant cells.

Figure 5. Clustering of lymphoma cell lines with differentially expressed JAK/STAT pathway genes. Significant JAK/STAT pathway
genes were clustered with all available lymphoma cell lines, shown in A. These genes were then clustered with only the cell lines from the
sensitive and resistant groups, as shown in B.

genes together with their function allows for a complete
view of potential regulatory mechanisms occurring
in a biological process. Reactome analysis was then
used to group genes based on their common pathways,
demonstrated in Table 7.
4. Discussion
The JAK-STAT pathway may play an important role in the
pathogenesis of lymphoma (2,16). In humans, the activator
of the JAK-STAT family comprises four JAKs (JAK 1, JAK
2, JAK 3, and tyrosine kinase 2 (TYK 2)) and seven STATs
(STAT 1, STAT 2, STAT 3, STAT 4, STAT 5a, STAT 5b, STAT 6)

proteins (5). JAK-STAT proteins play a key role in regulating
lymphoid homeostasis and immunity. This includes the
maintenance of the balance between the development of
T helper 1 (Th1) and T helper 2 (Th2), T-cell response,
regulatory T (Treg) cells, and the function of memory CD8+
cells in myeloid and lymphoid development (5). JAK-STAT
signaling is perversely activated in lymphoma by multiple
mechanisms, together with inappropriate autocrine and
paracrine cytokine stimulation. Genetic and epigenetic
changes of negative regulators of JAK/STAT signaling, such
as loss of function, SOCS1 mutations, and deletions of the
protein tyrosine phosphatase 2 (PTPN2), may also cause
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Table 4. List of pathways significant within the sensitive group.
GENESET PATHWAY

SIZE

NOM P

FDR q

1

Go_Enzyme_Inhibitor_Activity

19

0

0.013

2

Go_Secretory_Vesicle

32

0

0.064

3

Go_Secretory_Granule

27

0

0.157

4

Go_Vacuolar_Membrane

36

0

0.215

5

Go_Cell_Leading_Edge

26

0.002

0.232

6

Go_Vacuolar_Part

43

0.003

0.095

7

Go_Protein_Complex_Binding

53

0.003

0.189

8

Go_Vacuole

65

0.003

0.279

9

Go_Oxidation_Reduction_Process

45

0.005

0.321

10

Go_Transition_Metal_Ion_Binding

67

0.005

0.268

11

Go_Vesicle_Mediated_Transport

69

0.009

0.257

12

Go_Membrane_Microdomain

20

0.013

0.269

13

Go_Transport_Vesicle

24

0.014

0.261

14

Go_Golgi_Apparatus

78

0.014

0.393

15

Go_Lipid_Localization

18

0.015

0.3

16

Go_Lytic_Vacuole

31

0.016

0.282

17

Go_Hydrolase_Activity_Acting_On_Acid_Anhydrides

43

0.016

0.29

18

Go_Cytoskeletal_Protein_Binding

45

0.016

0.267

19

Go_Cytoskeleton

80

0.017

0.277

20

Go_Sulfur_Compound_Metabolic_Process

20

0.018

0.274

21

Go_Macromolecular_Complex_Binding

67

0.018

0.396

22

Go_Zinc_Ion_Binding

57

0.019

0.335

23

Go_Regulation_Of_Lipid_Metabolic_Process

18

0.022

0.276

24

Go_Locomotion

59

0.022

0.392

25

Go_Presynapse

17

0.024

0.327

26

Go_Golgi_Apparatus_Part

47

0.03

0.272

27

Go_Enzyme_Regulator_Activity

41

0.03

0.387

28

Go_Endocytosis

32

0.037

0.391

29

Go_Positive_Regulation_Of_Cytokine_Production

24

0.037

0.384

30

Go_Golgi_Membrane

36

0.042

0.408

deregulated JAK/STAT initiation in Hodgkin lymphoma,
primary mediastinal large B-cell lymphoma, diffuse large
B-cell lymphoma, follicular lymphoma, and Peripheral
T-cell lymphoma (13). As mentioned, one of the foremost
pathways taking part in the signal transductions of a wide
array of these cytokines is the JAK/STAT cascade. The JAK/
STAT pathway is crucial for many significant biological
processes, including broad immune and hematopoietic cell
functions (1).
Acquired mutations may influence the JAK/STAT
pathway by activating members of the JAK and STAT families
directly, inactivating proteins whose typical function is to
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deactivate the JAKs, or establishing autocrine signaling
loops that drive JAK-mediated multiplication. Some of
the mutations that are found to be linked to lymphoma
development directly target genes that encode elements
of the JAK/STAT pathway. JAK 1 and STAT 3 mutations
show this relationship between lymphoma development
and the JAK/STAT pathway (2). However, even in the
presence of STAT or JAK mutations, the whole functional
cytokine receptors, JAK and STAT, were required to
maintain activation and malignant cell proliferation (17).
STAT 3 and STAT 5b mutations are present in aggressive
lymphomas emerging from natural killer cells as well as
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Table 5. List of pathways significant within the resistant group.
GENESET PATHWAY

SIZE

NOM P

FDR q

1

ncRNA Processing

40

0

0

2

Ribosome Biogenesis

37

0

0

3

ncRNA Metabolic Process

44

0

0

4

RNA Catabolic Process

33

0

0

5

Organic Cyclic Compound Catabolic Process

40

0

0.001

6

Ribonucleoprotein Complex Biogenesis

42

0

0.001

7

rRNA Metabolic Process

35

0

0.001

8

Nuclear Transcribed mRNA Catabolic Process Nonsense Mediated Decay

27

0

0.002

9

Structural Constituent Of Ribosome

27

0

0.002

10

Translational Initiation

26

0

0.004

11

Ribonucleoprotein Complex

45

0

0.004

12

Cytosolic Part

25

0

0.005

13

Ribosomal Subunit

25

0

0.005

14

Protein Targeting To Membrane

27

0

0.005

15

Posttranscriptional Regulation Of Gene Expression

27

0

0.005

16

Amide Biosynthetic Process

40

0

0.005

17

Ribosome

27

0.002

0.006

18

Protein Localization To Endoplasmic Reticulum

26

0

0.009

19

Establishment Of Protein Localization To Endoplasmic

26

0

0.011

20

Cytosolic Ribosome

24

0

0.012

21

Regulation Of Cellular Amide Metabolic Process

24

0.003

0.015

22

RNA Processing

63

0

0.016

23

B Cell Activation

15

0

0.02

24

Immune Response Regulating Cell Surface Receptor

19

0

0.021

25

Multi Organism Metabolic Process

26

0.002

0.021

26

RNA Binding

100

0.001

0.024

27

Establishment Of Protein Localization To Membrane

31

0

0.038

28

Poly A RNA Binding

83

0

0.039

29

mRNA Metabolic Process

53

0

0.039

30

Structural Molecule Activity

46

0.003

0.086

the mutated STATs that are related to increased tyrosine
phosphorylation. They supply a growth benefit to natural
killer cells, which can be partially inhibited by a JAK 1 and
JAK 2 inhibitor (4).
Preliminary studies considering the efficacy of JAK
inhibitors illustrate that therapeutic agents targeting the
JAK/STAT signaling pathway can be used to treat patients
with lymphoma (3). On the other hand, ruxolitinibinduced JAK/STAT pathway inhibition in myelofibrosis is
associated with an elevated frequency of aggressive B-cell
lymphomas (6). Based on the results of our present in silico
study, there must be some concern for the development

of lymphoproliferative neoplastic disease in a given
patient under ruxolitinib since the drug affects numerous
genes that have a clear impact on the pathobiology of
lymphomas. Table 3 summarizes the list of genes present in
lymphoid cancer stem cells that were affected by ruxolitinib
usage and their clinical correlations. Thus, ruxolitinib
may potentially lead to the pathological expression of
the transcription factors important in lymphomagenesis,
neoplastic commitment on the progenitor lymphoid
cells, inhibition of repressor transcriptions protective
for lymphoma development, inhibition of apoptosis,
promotion of neoplastic proliferation, transcriptional
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Figure 6. GeneMANIA generated network showing interaction
patterns of JAK/STAT pathway and CSC marker gene sets
based on coexpression and genetic interactions. Input genes are
shown in blue (14 nodes), while the ones identified as related
by the program are shown in green. The coexpression-based
interactions are shown by purple edges, while the ones from
genetic interactions are shown in green.

activation, and proliferation of malignant neoplastic B
cells (Table 3). Hence, we fully agree with Porpaczy et al.
that the detection of a preexisting B-cell clone may identify
individuals at risk for lymphoma development and any
ruxolitinib candidate should undergo a bone marrow
biopsy procedure for the evaluation of clonal lymphoid
baseline proliferation (6). This suggestion is particularly
helpful for early stage myelofibrosis or PV since those
patients potentially have decades for survival (7,18,19).
Ruxolitinib is administered for PV just for the control of
symptoms, but if lymphoma due to ruxolitinib complicates
the clinical picture, the survival could be decreased from
about two decades to several months in a given PV patient.
Ruxolitinib is a JAK/STAT signaling pathway inhibitor
targeted drug with predictable pharmacobiological actions.
The main function of the JAK/STAT signaling pathway is
cellular proliferation in health and disease. The drug has
been approved for the treatment of patients with high- or
intermediate-risk myelofibrosis (MF) with symptomatic
splenomegaly. The development of lymphoma due to
ruxolitinib might be acceptable for a high-risk advanced
stage of MF. However, based on the results of our current
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study, the administration of ruxolitinib may not be rational
for symptom control only in early-stage MF, low-risk MF,
and PV patients for the potential pathobiological risk of
lymphoma development.
The clinical relevance of the novel results of our study
adds support to the concerns of Porpaczy et al. (6). If
pharmacobiological aspects of ruxolitinib are related to
the danger of the development of lymphoma in patients
with chronic myeloproliferative disorders, then decades
of usage of the drug could be harmful at least for the
patient subpopulation with already present preneoplastic
bone marrow lymphoid follicles. Clinicians dealing with
the management of chronic myeloproliferative disorders
should be aware of this fact and should clinicopathologically
check lymphoid neoplastic disorders before and during
the administration of ruxolitinib. Of course, myeloid and
lymphoid neoplasia are different diseases, but long-term
administration of JAK/STAT inhibitors may be located
at a crossroads to complicate lymphoma in a patient with
chronic myeloproliferative disease.
The development of any drug from bench side
to the clinic is very difficult, painful, and expensive.
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Table 6. The list of functions associated with differently grouped genes in the network.
GO ID

Description

q-value

Occurrences
in Sample

Occurrences
in Genome

GO:0007259

JAK-STAT cascade

3.24E-18

13

91

GO:0046427

positive regulation of JAK-STAT cascade

1.04E-08

7

45

GO:0060397

JAK-STAT cascade involved in growth hormone signaling pathway

1.48E-08

6

24

GO:0071378

cellular response to growth hormone stimulus

4.01E-08

6

31

GO:0060396

growth hormone receptor signaling pathway

4.01E-08

6

31

GO:0046425

regulation of JAK-STAT cascade

4.01E-08

7

61

GO:0060416

response to growth hormone

4.22E-08

6

32

GO:0042113

B cell activation

5.71E-08

8

119

GO:0042100

B cell proliferation

9.11E-07

6

54

GO:0046651

lymphocyte proliferation

2.97E-06

7

123

GO:0032943

mononuclear cell proliferation

3.03E-06

7

125

GO:0070661

leukocyte proliferation

4.29E-06

7

133

GO:0042531

positive regulation of tyrosine phosphorylation of STAT protein

8.43E-06

5

38

GO:0042509

regulation of tyrosine phosphorylation of STAT protein

1.68E-05

5

44

GO:0007260

tyrosine phosphorylation of STAT protein

2.46E-05

5

48

GO:0097285

cell-type specific apoptotic process

4.42E-05

7

194

GO:0018108

peptidyl-tyrosine phosphorylation

6.75E-05

7

210

GO:0042517

positive regulation of tyrosine phosphorylation of Stat3 protein

6.75E-05

4

23

GO:0018212

peptidyl-tyrosine modification

6.75E-05

7

210

GO:0050730

regulation of peptidyl-tyrosine phosphorylation

1.23E-04

6

138

GO:0016925

protein sumoylation

1.40E-04

4

28

GO:0050871

positive regulation of B cell activation

1.42E-04

4

29

GO:0071375

cellular response to peptide hormone stimulus

1.42E-04

7

244

GO:0042516

regulation of tyrosine phosphorylation of Stat3 protein

1.42E-04

4

29

GO:0005126

cytokine receptor binding

1.43E-04

6

148

GO:1901653

cellular response to peptide

1.43E-04

7

247

GO:0042503

tyrosine phosphorylation of Stat3 protein

1.63E-04

4

31

GO:0043434

response to peptide hormone

1.63E-04

7

255

GO:1901652

response to peptide

1.80E-04

7

260
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Table 7. The resulting pathways from Reactome analysis and the number of genes for each of them ordered by P-value.
Pathway identifier

Pathway name

#Entities
found

Entities
pValue

R-HSA-1280215

Cytokine Signaling in Immune system

10

1.55E-07

R-HSA-168256

Immune System

13

1.39E-06

R-HSA-112411

MAPK1 (ERK2) activation

2

1.13E-04

R-HSA-110056

MAPK3 (ERK1) activation

2

1.33E-04

R-HSA-1059683

Interleukin-6 signaling

2

2.27E-04

R-HSA-1170546

Prolactin receptor signaling

2

2.54E-04

R-HSA-112409

RAF-independent MAPK1/3 activation

2

6.10E-04

R-HSA-982772

Growth hormone receptor signaling

2

6.54E-04

R-HSA-6783589

Interleukin-6 family signaling

2

7.00E-04

R-HSA-8862803

Deregulated CDK5 triggers multiple neurodegenerative
pathways in Alzheimer’s disease models

2

7.46E-04

R-HSA-8863678

Neurodegenerative Diseases

2

7.46E-04

R-HSA-449147

Signaling by Interleukins

5

10.80E-03

R-HSA-76002

Platelet activation, signaling and aggregation

3

57.84E-03

R-HSA-2219530

Constitutive Signaling by Aberrant PI3K in Cancer

2

66.73E-03

R-HSA-198933

Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

3

74.69E-03

R-HSA-1280218

Adaptive Immune System

5

75.00E-03

R-HSA-5668541

TNFR2 non-canonical NF-kB pathway

2

79.43E-03

Sometimes unexpected pharmacobiological adverse
effects could complicate the treatment strategy with novel
drugs. Therefore, a well-developed scientific strategy is
absolutely necessary for the design of clinical studies at
all critical points. Ruxolitinib is the first clinically useful

targeted therapy in Ph*-negative MPNs. In the interest of
a clinically advanced approach to the study of this drug,
the progression of lymphoma development associated
with ruxolitinib in addition to the disease risk profile and
scoring of MPNs should be included.
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